Stifel initiated coverage of Olema Oncology (OLMA) with a Buy rating and $48 price target The firm, which “conservatively” models peak sales of $3.1B in 2035 for lead asset palazestrant, adds that endocrine therapy in ER+/HER2- could be “a $20B+ global market opportunity with plenty of room for many big players.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OLMA:
- Olema Pharmaceuticals CFO Departs; CEO Assumes Interim Role
- Olema Oncology announces departure of COO, CFO Shane Kovacs
- Apellis, Olema, Exicure, Immunovant, LivePerson Insider Shake-Up
- Piper Sandler Puts its Weight Behind 2 ‘Strong Buy’ Cancer Stocks
- Olema Highlights Palazestrant Strategy in New Investor Presentation